title: ¹⁸F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers.
abstract: OBJECTIVE
  To evaluate the accuracy of ¹⁸F-fluoride PET/computed tomography (CT) to detect bone metastases (BMs) in a breast and prostate cancer population, using magnetic resonance imaging (MRI) or thin-slice CT as a gold standard.
  
  
  METHODS
  We have prospectively included 34 patients with breast (N=24) or prostate cancer (N=10) at high risk of BMs. Whole-body PET/CT (low-dose CT) and bone scintigraphy (BS) with single photon emission CT were obtained for all 34 patients and the results compared with a radiological gold standard.
  
  
  RESULTS
  Out of the 386 foci detected by PET/CT, 219 (56.7%) could be verified by CT or MRI. Eighty-six additional foci were detected by BS (n=46) or seen only by CT (n=9), MRI (n=23), or both CT and MRI (n=8). The total number of verified lesions was therefore 274 (58.1%), including 119 (43.4%) benign and 155 (56.6%) BM. The sensitivity, specificity, and accuracy of ¹⁸F-fluoride PET/CT were 76, 84.2, and 80%, respectively. For BS, they were 44.8, 79.2, and 60%, respectively. Sensitivity significantly decreased for the lytic lesions. The accuracy of PET/CT was significantly superior to BS for pelvic and lumbar lesions. PET/CT provided a correct diagnosis (M+/M0) in 32 of 33 patients (one false positive) compared with 28 of 33 with BS (four false positive, one false positive).
  
  
  CONCLUSIONS
  ¹⁸F-fluoride PET/CT is significantly more accurate than BS for detecting BMs from breast and prostate cancers.
authors.affiliation: University of Liège, Belgium.
authors.forename: Nadia
authors.initials: N
authors.lastname: Withofs
authors.forename: Benjamin
authors.initials: B
authors.lastname: Grayet
authors.forename: Tino
authors.initials: T
authors.lastname: Tancredi
authors.forename: Andrée
authors.initials: A
authors.lastname: Rorive
authors.forename: Christine
authors.initials: C
authors.lastname: Mella
authors.forename: Fabrice
authors.initials: F
authors.lastname: Giacomelli
authors.forename: Frédéric
authors.initials: F
authors.lastname: Mievis
authors.forename: Joël
authors.initials: J
authors.lastname: Aerts
authors.forename: David
authors.initials: D
authors.lastname: Waltregny
authors.forename: Guy
authors.initials: G
authors.lastname: Jerusalem
authors.forename: Roland
authors.initials: R
authors.lastname: Hustinx
mesh_terms: D001859:Bone Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000473:pathology*; D012015:Reference Standards; D012680:Sensitivity and Specificity; D013669:Technetium Tc 99m Medronate; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D019788:Fluorodeoxyglucose F18; D013669:Technetium Tc 99m Medronate